Trial Profile
Clinical Trials Insight: 700021100
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2007
Price :
$35
*
At a glance
- Drugs Sparsentan (Primary)
- Indications Diabetic nephropathies; Hypertension
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pharmacopeia
- 22 Feb 2007 New trial record.